Inhibikase Therapeutics, Inc. (IKT) Form 10-Q — Aug 11, 2026
Inhibikase Therapeutics reported a Q2 2026 net loss of $19.6 million, nearly double the $9.9 million loss a year earlier, as Phase 3 spending drove research and development expense up 154% to $13.4 million. First-half net loss reached $36.0 million, with operating cash burn of $24.5 million versus $9.7 million in the prior-year period. The company held $159.0 million in cash, equivalents and marketable securities at June 30, 2026, and in July sold 25.3 million shares through its Jefferies ATM for $50.5 million gross, including a 25 million share, $50.0 million block purchase by RA Capital Management.
Key figures
- Eps
- -0.11 (Q2 2026); -0.21 (1H 2026), basic and diluted
- Revenue
- 0
- Total Assets
- 163588612
- Cash Position
- 31206707
- Shares Outstanding
- 139535900
- Rd Expense Q2
- 13393464
- Sga Expense Q2
- 7657531
- Cmo Commitments
- $9.8 million
- Cro Commitments
- $106.6 million
- Nov2025 Offering Net
- $107.6 million
- Marketable Securities
- 127812140
- Phase3 Sites Activated
- 43
- Rd Expense Q2 Prior Year
- 5270967
- July2026 ATMGross Total
- $50.5 million for 25,261,500 shares
- Abli Milestone Potential
- $47.5 million plus double-digit royalties
- Phase3 Country Approvals
- 26
- Rd Expense Growth Q2 Percent
- 154.1
- Weighted Avg Shares Q2 2026
- 174571543
- Oct2024 Private Placement Net
- $99.6 million
- Ra Capital Block Purchase Gross
- $50.0 million for 25,000,000 shares (July 2026)
- Total Cash Securities Marketable
- $159.0 million
- Potential Dilutive Shares Options Warrants
- 170788778
Price after filing
Close on the filing date to close N calendar days later (from $2.46). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.